>  
Report Detail

Gastric Motility Disorder – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 40

Gastric Motility Disorder – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Gastric Motility Disorder – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastric Motility Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder. Gastric Motility Disorder – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastric Motility Disorder.
- A review of the Gastric Motility Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastric Motility Disorder pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastric Motility Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastric Motility Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Gastric Motility Disorder – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastric Motility Disorder Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Gastric Motility Disorder 7
Gastric Motility Disorder Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Gastric Motility Disorder Therapeutics - Products under Development by Companies 14
Companies Involved in Gastric Motility Disorder Therapeutics Development 15
Theravance, Inc. 15
Helsinn Healthcare S.A. 16
Tranzyme Pharma, Inc. 17
Concert Pharmaceuticals, Inc. 18
Elixir Pharmaceuticals, Inc. 19
Gastric Motility Disorder - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ulimorelin hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
TZP-102 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
EX-1314 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
velusetrag - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ipamorelin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
TD-8954 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Gastric Motility Disorder Therapeutics - Drug Profile Updates 34
Gastric Motility Disorder - Product Development Milestones 38
Featured News & Press Releases 38
Jun 06, 2012: Tranzyme To Present Data On TZP-102 At American Diabetes Association Scientific Sessions 38
Jun 01, 2012: RaQualia Pharma Initiates First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010 38
Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Gastric Motility Disorder, H2 2012 7
Products under Development for Gastric Motility Disorder - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Theravance, Inc., H2 2012 15
Helsinn Healthcare S.A., H2 2012 16
Tranzyme Pharma, Inc., H2 2012 17
Concert Pharmaceuticals, Inc., H2 2012 18
Elixir Pharmaceuticals, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Gastric Motility Disorder Therapeutics - Drug Profile Updates 34

List of Figures
Number of Products under Development for Gastric Motility Disorder, H2 2012 7
Products under Development for Gastric Motility Disorder - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24
  • How to Treat Arthritis Effectively ?
    The word arthritis stands for inflammation of joints. It is an umbrella term for over 100 diseases that cause pain, discomfort, disability and several other symptoms amongst individuals. Osteoarthritis is one of the most common types of arthritis, which affects elderly. Several other forms of this disease may affect individuals at a very young age [...]
  • Benefits of Set top Boxes Amidst the Wave of Digitization
    A set top unit or box is a useful device that provides content through television sets. Set top box is a term that refers to a device, which is used for broadcasting the content. It is different from the devices that help simple recording of media, such as DVDs. Cable operators and satellite companies provide [...]
  • What are the Treatments for Alzheimer’s Disease ?
    Alzheimer’s disease is one of the most common types of dementia. Dementia is the condition defined by significant loss of global cognitive ability in a healthy person. This loss is beyond the normal aging process and it only worsens with the age. Alzheimer’s disease is a serious mental health condition and a progressive brain disease [...]
  • Book Publishing Process- A Brief Overview
    Publishing is the process of making certain information available for the public. Many a times, authors have their own publication house or they prefer publishing their books on their own. However, those who are not aware of the media that delivers their content find the book publishing process daunting. Contrary to this belief, book-publishing process [...]
  • Understand the Basics before Entering the World of IPTV
    IPTV or internet protocol television is an innovative technology, which has changed the appearance of the television programming across the globe. Internet protocol television provides television programming through broadband connection, which works according to the internet protocols. Television viewers who want to enjoy this viewing experience need to subscribe to the IPTV service and buy [...]
  • Argentina Pharmaceuticals and Healthcare Report Q3 2013
    "...... welldeveloped local manufacturing force and its strategic location mean Argentina remains an appealing prospect.. Headline Expenditure Projections: Pharmaceuticals: ARS39.4bn (US$8.7bn) in 2012 to ARS49.4bn (US$8.9bn) in 2013; +25.3% in local curren......"
  • Hong Kong Pharmaceuticals and Healthcare Report Q3 2013
    "......increasing openness of the Chinese market, which decreases the necessity for firms to set up bases in Hong Kong. Headline Expenditure Projections ? Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 to HKD10.77bn (US$1.39bn) in 2013; +4.5% in local curr......"
  • New Zealand Pharmaceuticals and Healthcare Report Q3 2013
    "......n the country. Headline Expenditure Forecasts ? Pharmaceuticals: NZD1.36bn (US$1.10bn) in 2012 to NZD1.37bn (US$1.06bn) in 2013; +0.5% in local currency and -3.8% in US dollar terms. ? Healthcare: NZD21.22bn (US$17.19bn) in 2012 to NZD21.96bn (US$17......."
  • Taiwan Pharmaceuticals and Healthcare Report Q3 2013
    "......e, the Bureau of National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tightening its oversight of prescription drug distribution. Therefore, we envisage that main drivers of the Taiwanese pharmaceutical market de......"
  • Zambia Pharmaceuticals and Healthcare Report Q3 2013
    "...... rarely has access to specialist services. There are also other differences in rural/urban healthcare provision, such as those relating to the drug supply chain, drug quality concerns and a lack of modern healthcare facilities in much of the country......."